Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Abstract 4388: Novel small molecule on state inhibitor for GTP bound pan-KRAS (G12) mutations

Chandru Gajendran, Naveen M. Sadhu, Ramachandraiah Gosu, Mohammed Zainuddin, Dhanalakshmi Sivanandhan, Sridharan Rajagopal

Cancer Res (2025) 85 (8_Supplement_1): 4388.

https://doi.org/10.1158/1538-7445.AM2025-4388

Published: 21 April 2025

View articletitled, Abstract 4388: Novel small molecule on state inhibitor for GTP bound pan-KRAS (G12) mutations

Journal Articles

Abstract 6214: OncodynamiX as an artificial intelligence (AI) based platform for precision medicine

Dhanalakshmi Sivanandhan, Priyanka R. Bhargav, Sumanth M. Vasista, Sirisha Narayanbhatla, Suman Kamath, Oguru Sailaja, Dipanjan Chakraborty, Sundaresh Babu

Cancer Res (2024) 84 (6_Supplement): 6214.

https://doi.org/10.1158/1538-7445.AM2024-6214

Published: 22 March 2024

View articletitled, Abstract 6214: OncodynamiX as an artificial intelligence (AI) based platform for precision medicine

Journal Articles

Abstract 6269: JBI-778, a novel brain-penetrant small molecule PRMT5 inhibitor for treatment of cancer

Dhanalakshmi Sivanandhan, Chandru Gajendran, Naveen Sadhu M, Zainuddin Mohammed, Ramachandraiah Gosu, Divsha Sher, Shahar Mansur, Dinorah Friedmann-Morvinski, Sridharan Rajagopal, Luca Rastelli

Cancer Res (2023) 83 (7_Supplement): 6269.

https://doi.org/10.1158/1538-7445.AM2023-6269

Published: 04 April 2023

View articletitled, Abstract 6269: JBI-778, a novel brain-penetrant small molecule PRMT5 inhibitor for treatment of cancer

Journal Articles

Abstract B029: LSD1-HDAC6 dual inhibitor JBI-802 is an epigenetic modulating agent with a novel mechanism of action that target MYC amplification in multiple neuroendocrine tumor types

Dhanalakshmi Sivanandhan, Sridharan Rajagopal, Chandru Gajendran, Naveen Sadhu, Mohd Zainuddin, Ramachandraiah Gosu, Luca Rastelli

Cancer Res (2022) 82 (23_Supplement_2): B029.

https://doi.org/10.1158/1538-7445.CancEpi22-B029

Published: 01 December 2022

View articletitled, Abstract B029: LSD1-HDAC6 dual inhibitor JBI-802 is an epigenetic modulating agent with a novel mechanism of action that target MYC amplification in multiple neuroendocrine tumor types

Journal Articles

A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

Hui Deng, Cindy Lin, Laura Garcia-Gerique, Shuyu Fu, Zachary Cruz, Erin E. Bonner, Matthew Rosenwasser, Sridharan Rajagopal, M Naveen Sadhu, Chandru Gajendran, Mohd Zainuddin, Ramachandraiah Gosu, Dhanalakshmi Sivanandhan, Miriam A. Shelef, Brian Nam, Dan T. Vogl, Dmitry I. Gabrilovich, Yulia Nefedova

Cancer Res (2022) 82 (19): 3561–3572.

https://doi.org/10.1158/0008-5472.CAN-21-4045

Published: 04 October 2022

View articletitled, A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

Includes: Supplementary data

Journal Articles

Abstract 2646: Novel, isoform selective PAD4 inhibitors for the treatment of cancer

Dhanalakshmi Sivanandhan, Sridharan Rajagopal, Chandru G, Mohd Zainuddin, Naveen Sadhu, Ramachandraiah Gosu, Luca Rastelli, Amir Siddiqui, Sharad Singh, Rudresh G, Sadanand Mullurwar, Saravanan Kandan, Santosh Vishwakarma, Gurulingappa Hallur, Ravi Trivedi, Jeyaraj D A

Cancer Res (2022) 82 (12_Supplement): 2646.

https://doi.org/10.1158/1538-7445.AM2022-2646

Published: 15 June 2022

View articletitled, Abstract 2646: Novel, isoform selective PAD4 inhibitors for the treatment of cancer

Journal Articles

Abstract 1630: Novel, small molecule inhibitors of PD-L1/PD-1 interaction

Dhanalakshmi Sivanandhan, Sridharan Rajagopal, Naveen Sadhu M, Chandru Gajendran, Chandregowda venkateshappa, Muralidhar Reddy, Pendyala Satya Kishore, Pratima Deshpande, Sundarajan kannan, Tabassum Sahareen, Santhosh Viswakarma, Amir Siddiqui, Mohammed Zainuddin, Rudresh G, Prashanthi Daram, Ramchandraiah Gosu, Rashmi Rekha Devi

Cancer Res (2021) 81 (13_Supplement): 1630.

https://doi.org/10.1158/1538-7445.AM2021-1630

Published: 01 July 2021

View articletitled, Abstract 1630: Novel, small molecule inhibitors of PD-L1/PD-1 interaction

Journal Articles

Abstract 1128: Selective, novel, small molecule PRMT5 inhibitors for treatment of cancer

Dhanalakshmi Sivanandhan, Sridharan Rajagopal, Naveen Sadhu M, Chandru Gajendran, Saravanan Vadivelu, Natarajan Tamizharasan, Indu N. Swamy, Santhosh Viswakarma, Amir Siddiqui, Saif wahid, Mohammed Zainuddin, Rudresh G, Prashanthi Daram, Ramchandraiah Gosu, Dinesh Tiagaraj, Shivani Garapaty, Sreekala Nair, Namratha Kapoor

Cancer Res (2021) 81 (13_Supplement): 1128.

https://doi.org/10.1158/1538-7445.AM2021-1128

Published: 01 July 2021

View articletitled, Abstract 1128: Selective, novel, small molecule PRMT5 inhibitors for treatment of cancer

Journal Articles

Abstract 1756: JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer

Dhanalakshmi Sivanandhan, Sridharan Rajagopal, Sreekala Nair, Basavaprabhu B, Reshma Dhkar, Santosh Viswakarma, Amir Siddiqui, Mohd Zainuddin, Rudresh G, Prashanthi Daram, Sunil Mohire, Krishnakumar V

Cancer Res (2020) 80 (16_Supplement): 1756.

https://doi.org/10.1158/1538-7445.AM2020-1756

Published: 15 August 2020

View articletitled, Abstract 1756: JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer

Journal Articles

Abstract 11: Novel dual inhibitors of LSD1-HDAC6/8 for treatment of cancer

Cancer Res (2019) 79 (13_Supplement): 11.

https://doi.org/10.1158/1538-7445.AM2019-11

Published: 01 July 2019

View articletitled, Abstract 11: Novel dual inhibitors of LSD1-HDAC6/8 for treatment of cancer

Journal Articles

Abstract 4856: Novel, small-molecule PRMT5 inhibitors for treatment of cancer

Dhanalakshmi Sivanandhan, Shivani Garapaty, Saravanan Vadivelu, Guru Pavan Kumar Seerapu, Reshma Das, Ronodip Kar, Anuj Kumar Singh, Venkatesha Ashokkumar Venkateshappa, Natarajan Tamizharasan, Indu N. Swamy, Nagendra Nagaraju, Subramaniyam Kanagaraj, Sayanti Sarkar, Jagadish D. Tibhe, Rudresh G, Mohd Zainuddin, Saravanan Kandan, Sridharan Rajagopal, Sriram Rajagopal

Cancer Res (2018) 78 (13_Supplement): 4856.

https://doi.org/10.1158/1538-7445.AM2018-4856

Published: 01 July 2018

View articletitled, Abstract 4856: Novel, small-molecule PRMT5 inhibitors for treatment of cancer

Journal Articles

Abstract 5860: Novel, first-in-class dual inhibitors of lysine specific demethylase 1 (LSD1) and histone deacetylatse 1 (HDAC) for treatment of cancer

Cancer Res (2018) 78 (13_Supplement): 5860.

https://doi.org/10.1158/1538-7445.AM2018-5860

Published: 01 July 2018

View articletitled, Abstract 5860: Novel, first-in-class dual inhibitors of lysine specific demethylase 1 (LSD1) and histone deacetylatse 1 (HDAC) for treatment of cancer

Journal Articles

Abstract 5578: Small molecule modulators to understand the role of IDO1 and TDO2 in cancer

Shivani Rao Garapaty, Dhanalakshmi Sivanandhan, Guru Pavan Kumar Seerapu, Surendra Naidu, Shalini Chakelam, Pradeep Nagaraj, Reshma Das, Saravanan Vadivelu, Pravin Iyer, Chandrika Mulakala, Kannan Murugan, Somnath Mondal, Anjali Gautam, Saravanan Kandan, Manish Kumar Thakur, Sridharan Rajagopal, Sriram Rajagopal

Cancer Res (2017) 77 (13_Supplement): 5578.

https://doi.org/10.1158/1538-7445.AM2017-5578

Published: 01 July 2017

View articletitled, Abstract 5578: Small molecule modulators to understand the role of IDO1 and TDO2 in cancer

Journal Articles

Abstract 187: ASN0007, a potent ERK1/2 inhibitor with strong antitumor activity in multiple RAS mutant models

Sanjeeva P. Reddy, Dhanalakshmi Sivanandhan, Raghava Reddy Kethiri, Sreekala Nair, Purushottam Dewang, Mohd Zainuddin, Krishnakumar Vaithilingam, Roger A. Smith, Sandeep Gupta, Scott K. Thompson

Cancer Res (2016) 76 (14_Supplement): 187.

https://doi.org/10.1158/1538-7445.AM2016-187

Published: 15 July 2016

View articletitled, Abstract 187: ASN0007, a potent ERK1/2 inhibitor with strong antitumor activity in multiple RAS mutant models

Journal Articles

Abstract PR09: EZH2 inhibitors reveal broad EZH2 dependencies in multiple myeloma

Shilpi Arora, Kaylyn Williamson, Srividya Balasubramanian, Jennifer Busby, Shivani Garapaty-Rao, Charlie Hatton, Dhanalakshmi Sivanandhan, Barbara Bryant, Emmanuel Normant, Patrick Trojer

Cancer Res (2016) 76 (2_Supplement): PR09.

https://doi.org/10.1158/1538-7445.CHROMEPI15-PR09

Published: 14 January 2016

View articletitled, Abstract PR09: EZH2 inhibitors reveal broad EZH2 dependencies in multiple myeloma

Journal Articles

Abstract 3509: Novel dual inhibitors of LSD1-HDAC for treatment of cancer

Dhanalakshmi Sivanandhan, Sridharan Rajagopalan, Sreekala Nair, Purushottam Dewang, Durga Prasanna Kumar, Chandrika Mulakala, Lavanya Mahadevan, Neema Skariah, Venkata Giri Kavuru, Damodara Kuntrapaku, Suchitra Sajja, Mohammad Zainuddin, Krishnakumar V, Ritu Singh, Swarnakumari V, Ramachandraiah Gosu, Jayashree Aiyar, Pravin Iyer, Sriram Rajagopal

Cancer Res (2015) 75 (15_Supplement): 3509.

https://doi.org/10.1158/1538-7445.AM2015-3509

Published: 01 August 2015

View articletitled, Abstract 3509: Novel dual inhibitors of LSD1-HDAC for treatment of cancer

Journal Articles

Abstract LB-232: Potent, novel small molecule inhibitors targeting EGFR L858R/T790M mutation for non-small cell lung cancer

Dhanalakshmi Sivanandhan, Payal K. Parikh, Avinash Sheshachalam, Chandregowda V, Rajagopal Bhakthavatchalam, Manish Gupta, Sanjeev Giri, Krishnakumar V

Cancer Res (2014) 74 (19_Supplement): LB-232.

https://doi.org/10.1158/1538-7445.AM2014-LB-232

Published: 01 October 2014

View articletitled, Abstract LB-232: Potent, novel small molecule inhibitors targeting EGFR L858R/T790M mutation for non-small cell lung cancer

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 4388: Novel small molecule on state inhibitor for GTP bound pan-KRAS (G12) mutations

Abstract 6214: OncodynamiX as an artificial intelligence (AI) based platform for precision medicine

Abstract 6269: JBI-778, a novel brain-penetrant small molecule PRMT5 inhibitor for treatment of cancer

Abstract B029: LSD1-HDAC6 dual inhibitor JBI-802 is an epigenetic modulating agent with a novel mechanism of action that target MYC amplification in multiple neuroendocrine tumor types

A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

Abstract 2646: Novel, isoform selective PAD4 inhibitors for the treatment of cancer

Abstract 1630: Novel, small molecule inhibitors of PD-L1/PD-1 interaction

Abstract 1128: Selective, novel, small molecule PRMT5 inhibitors for treatment of cancer

Abstract 1756: JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer

Abstract 11: Novel dual inhibitors of LSD1-HDAC6/8 for treatment of cancer

Abstract 4856: Novel, small-molecule PRMT5 inhibitors for treatment of cancer

Abstract 5860: Novel, first-in-class dual inhibitors of lysine specific demethylase 1 (LSD1) and histone deacetylatse 1 (HDAC) for treatment of cancer

Abstract 5578: Small molecule modulators to understand the role of IDO1 and TDO2 in cancer

Abstract 187: ASN0007, a potent ERK1/2 inhibitor with strong antitumor activity in multiple RAS mutant models

Abstract PR09: EZH2 inhibitors reveal broad EZH2 dependencies in multiple myeloma

Abstract 3509: Novel dual inhibitors of LSD1-HDAC for treatment of cancer

Abstract LB-232: Potent, novel small molecule inhibitors targeting EGFR L858R/T790M mutation for non-small cell lung cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only